An interventional study of Innovative pre-hospital emergency transport system for acute ischemic stroke in Acute Ischemic Stroke, sponsored by Xuanwu Hospital, Beijing. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment
This study aims to develop and evaluate an innovative prehospital emergency transport system for patients with acute ischemic stroke to reduce delays in reperfusion treatment. The system integrates artificial intelligence-based prehospital stroke assessment, selected examinations and blood collection in the ambulance, and real-time information sharing between emergency medical services and the receiving hospital. Its effectiveness will be evaluated in a multicenter, stepped-wedge cluster randomized controlled trial comparing the innovative system with standard prehospital care. The primary outcome is the time from hospital arrival to intravenous thrombolysis.
2,653 studies on the registry are indexed under Ischemic Stroke; 936 are open to participants now.
This study's planned enrollment of 320 is above the median of 120 across 1,799 interventional studies indexed under Ischemic Stroke.
Browse Ischemic Stroke studies →Xuanwu Hospital, Beijing is the lead sponsor of 357 studies on the registry; 226 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Hospitals：
Patients：
Exclusion Criteria:
Hospitals：
1. Hospitals participating in other research projects aimed at improving pre-hospital emergency processes or stroke thrombolysis treatment.
Patients：
Participants in this arm receive the innovative pre-hospital emergency transport system for 9 months.
Behavioral: Innovative pre-hospital emergency transport system for acute ischemic stroke
Participants in this arm receive the innovative pre-hospital emergency transport system for 6 months.
Behavioral: Innovative pre-hospital emergency transport system for acute ischemic stroke
Participants in this arm receive the innovative pre-hospital emergency transport system for 3 months.
Behavioral: Innovative pre-hospital emergency transport system for acute ischemic stroke
The system includes an AI-based pre-hospital stroke assessment tool (e.g., G-FAST score), rapid blood glucose testing, pre-hospital blood draws, ECG testing, and pre-thrombolysis informed consent. Real-time information sharing between the ambulance and the hospital is implemented to ensure coordinated care. All participants also receive standard in-hospital stroke evaluation and treatment.
Door-to-Needle Time
Time from hospital arrival to intravenous thrombolysis administration, measured in minutes.
Time frame: Up to 24 hours after symptom onset or last known well.
Onset-to-Needle Time
Time from symptom onset to intravenous thrombolysis administration, measured in minutes.
Time frame: Up to 24 hours after symptom onset or last known well.
Door-to-Imaging Time
Time from hospital arrival to completion of neuroimaging (CT/MRI), measured in minutes.
Time frame: Up to 24 hours after symptom onset or last known well.
72-Hour National Institutes of Health Stroke Scale Score
The National Institutes of Health Stroke Scale (NIHSS) assesses neurological impairment. Scores range from 0 to 42, with higher scores indicating more severe neurological deficits and a worse neurological status.
Time frame: 72 ± 6 hours after hospital admission.
National Institutes of Health Stroke Scale Score at Discharge or Day 7
The National Institutes of Health Stroke Scale (NIHSS) assesses neurological impairment. Scores range from 0 to 42, with higher scores indicating more severe neurological deficits and a worse neurological status.
Time frame: At hospital discharge or 7 days after hospital admission, whichever occurs first.
90-Day modified Rankin Scale Score
The distribution of modified Rankin Scale score at 90 days, on which scores range from 0 (no neurologic deficit) to 6 (death), with higher scores indicating greater disability and a worse functional outcome.
Time frame: 90 days after hospital discharge
Symptomatic Intracranial Hemorrhage
Proportion of patients with symptomatic intracranial hemorrhage following intravenous thrombolysis, defined according to ECASS III criteria.
Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks.
All-Cause Mortality
All-cause mortality rate at 90 days after hospital discharge.
Time frame: 90 days after hospital discharge.
Plan to share: No — Due to the protection of participant privacy and institutional review board requirements, individual participant data (IPD) will not be shared publicly.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 569 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 12 months is below that.
Counting every sponsor, half of 652 studies reached it within 26 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.